NeuExcell Therapeutics is a preclinical gene therapy company focusing on improving the lives of patients suffering from neurodegenerative diseases. The company has discovered a disruptive technology that focuses on regenerating neurons in the brain to restore damaged neuronal tissue. This powerful platform has the potential to transform patient outcomes and change lives.


We are now rapidly expanding our R&D efforts, toward our goal of developing effective and safe treatments for serious neurodegenerative diseases including stroke, Huntington’s Disease, ALS, and Traumatic Brain Injury.